Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women

[1]  D. Burr,et al.  Raloxifene enhances vertebral mechanical properties independent of bone density. , 2006, Bone.

[2]  Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society , 2006, Menopause.

[3]  S. Cummings.  LIFT study is discontinued , 2006, BMJ : British Medical Journal.

[4]  S. Cummings,et al.  Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  H. Kloosterboer.  Tissue-selectivity: the mechanism of action of tibolone. , 2004, Maturitas.

[6]  A. Genazzani,et al.  A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women , 2004, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[7]  A. Genazzani,et al.  The osteoporosis dilemma , 2004, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[8]  H. Genant,et al.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.

[9]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[10]  Robert Marcus,et al.  Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women , 2003, Osteoporosis International.

[11]  O. Johnell,et al.  Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. , 2003, Human reproduction.

[12]  H. Kloosterboer,et al.  Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[14]  S. Gabriel,et al.  Mortality, Disability, and Nursing Home Use for Persons with and without Hip Fracture: A Population‐Based Study , 2002, Journal of the American Geriatrics Society.

[15]  G. Guyatt,et al.  V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women , 2002 .

[16]  J. Reginster,et al.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[18]  C. Benhamou,et al.  Randomized, Double-masked, 2-year Comparison of Tibolone with 17β-Estradiol and Norethindrone Acetate in Preventing Postmenopausal Bone Loss , 2002, Osteoporosis International.

[19]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[20]  J. Gallagher,et al.  Prevention of Bone Loss With Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies , 2002 .

[21]  G. Guyatt,et al.  Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .

[22]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. , 2002, Endocrine reviews.

[23]  J. Robinson,et al.  Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. , 2002, Climacteric : the journal of the International Menopause Society.

[24]  J. Gallagher,et al.  Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  A. Ederveen,et al.  Tibolone Exerts Its Protective Effect on Trabecular Bone Loss Through the Estrogen Receptor , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  C. Christiansen,et al.  Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.

[27]  R. Harrison,et al.  Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women , 2000, Menopause.

[28]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[29]  P. Pavlov,et al.  Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. , 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[30]  P. Garnero,et al.  Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene , 1999, Osteoporosis International.

[31]  B. Riggs,et al.  Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  J. Studd,et al.  A Randomized Study of Tibolone on Bone Mineral Density in Osteoporotic Postmenopausal Women With Previous Fractures , 1998, Obstetrics and gynecology.

[33]  D. Thiebaud,et al.  A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. , 1998, Climacteric : the journal of the International Menopause Society.

[34]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[35]  R. Heaney,et al.  Raloxifene and estrogen: comparative bone-remodeling kinetics. , 1997, The Journal of clinical endocrinology and metabolism.

[36]  J. Casez,et al.  Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β‐Estradiol and Dydrogesterone , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  C. Christiansen,et al.  The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. , 1997, Bone.

[38]  H. Bennink,et al.  Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. , 1996, Bone.

[39]  C. Christiansen,et al.  Tibolone: prevention of bone loss in late postmenopausal women. , 1996, The Journal of clinical endocrinology and metabolism.

[40]  S. Chandrasekhar,et al.  Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. , 1996, Bone.

[41]  C. Cooper,et al.  Perspective how many women have osteoporosis? , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  P. Geusens,et al.  Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. , 1991, Maturitas.